GlassScriptPhysician profile
Michael Hien Bien
NPI 1689680654
$27,980.42
in general payments reported to CMS, 2019-2025
18 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $78.99 · 2021: $939 · 2022: $18K · 2023: $7,373 · 2024: $504 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,350 · Food and Beverage: $2,114 · Travel and Lodging: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,350.00 |
| Food and Beverage | $2,113.75 |
| Travel and Lodging | $102.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26,238.46 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $285.36 | 2019-2025 | Krystexxa |
| Akebia Therapeutics INC | $231.03 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $156.74 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $147.74 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $126.64 | 2019-2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $125.00 | 2022 | |
| Fresenius USA Marketing, INC. | $93.70 | 2020-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $88.96 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $83.98 | 2022-2024 | |
| Novo Nordisk INC | $82.80 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $66.86 | 2023 | Mounjaro |
| Calliditas Therapeutics US INC. | $57.36 | 2022-2023 | Tarpeyo |
| Cormedix INC. | $54.91 | 2024-2025 | Defencath |
| Mallinckrodt Hospital Products INC. | $51.61 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $48.39 | 2022-2023 | Benlysta |
| Ardelyx, INC. | $22.25 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $18.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.